New Treatment Targets Natural Tears For Dry Eyes | OphthalmologyWeb: The Ultimate Online Resource for Ophthalmologists

Thursday, November 25, 2010

Email

Comments

Allergan Inc.

Allergan is pleased to announce that Health Canada has approved RESTASIS® (cyclosporine) ophthalmic emulsion, 0.05% w/v for the treatment of moderate to moderately severe Dry Eye disease ("Dry Eye"). RESTASIS® is the first prescription eye drop to target the underlying cause of chronic Dry Eye.

Refractive Products and Equipment »

Muller's muscle is responsible for approximately 5 mm of eyelid elevation. (True/False)
1. True
2. False
Check The Answer

CareCloud Charts For Ophthalmology
Get all of the tools you need to deliver... view product
CareCloud Central
CareCloud Central is a medical practice ... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us